1. Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials
- Author
-
Laila A. Gharzai, Julia Pakela, Elizabeth M. Jaworski, Issam El Naqa, Jennifer Shah, Peter G. Hawkins, Matthew E. Spector, Carol R. Bradford, Steven B. Chinn, Kelly Malloy, Robbi Kupfer, Andrew Shuman, Robert Morrison, Chaz L. Stucken, Andrew Rosko, Mark E. Prince, Keith Casper, Avraham Eisbruch, Gregory Wolf, Paul L. Swiecicki, Francis Worden, and Michelle L. Mierzwa
- Subjects
Locally advanced laryngeal cancer ,Bioselection imaging ,Chemoradiation ,Laryngectomy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and purpose: Bioselection with induction chemotherapy in larynx cancer is associated with excellent larynx preservation and disease-specific survival but requires visual inspection of the primary tumor. We retrospectively compare clinical and imaging response in bioselected patients to develop predictive models of surgeon-assessed response (SR), laryngectomy-free survival (LFS), and overall survival (OS) in bioselected patients. Materials and methods: In a secondary analysis of patients on two single-institution bioselection trials, model building used a regularized regression model (elastic-net) and applied nested cross-validation. Logistic regression-based model was used to predict SR and Cox proportional hazard-based models were used to predict LFS and OS. Results: In 115 patients with a median age of 57 years, most patients had supraglottic tumors (73.0%) and T3/T4 disease (94.8%). Definitive treatment was chemoradiation in 76.5% and laryngectomy in 23.5%. Change in primary tumor (OR = 5.78, p
- Published
- 2022
- Full Text
- View/download PDF